ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Research Article
Revised

Association of smoking status with hospitalisation for COVID-19 compared with other respiratory viruses a year previous: a case-control study at a single UK National Health Service trust

[version 3; peer review: 2 approved]
PUBLISHED 17 Jan 2022
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Emerging Diseases and Outbreaks gateway.

This article is included in the Coronavirus (COVID-19) collection.

Abstract

Background: It is unclear whether smoking increases the risk of COVID-19 hospitalisation. We first examined the association of smoking status with hospitalisation for COVID-19 compared with hospitalisation for other respiratory viral infections a year previous. Second, we examined the concordance between smoking status recorded on the electronic health record (EHR) and the contemporaneous medical notes.
Methods: This case-control study enrolled adult patients (446 cases and 211 controls) at a single National Health Service trust in London, UK. The outcome variable was type of hospitalisation (COVID-19 vs. another respiratory virus a year previous). The exposure variable was smoking status (never/former/current smoker). Logistic regression analyses adjusted for age, sex, socioeconomic position and comorbidities were performed. The study protocol and analyses were pre-registered in April 2020 on the Open Science Framework.
Results: Current smokers had lower odds of being hospitalised with COVID-19 compared with other respiratory viruses a year previous (ORadj=0.55, 95% CI=0.31-0.96, p=.04). There was no significant association among former smokers (ORadj=1.08, 95% CI=0.72-1.65, p=.70). Smoking status recorded on the EHR (compared with the contemporaneous medical notes) was incorrectly recorded for 168 (79.6%) controls (χ2(3)=256.5, p=<0.001) and 60 cases (13.5%) (χ2(3)=34.2, p=<0.001).
Conclusions: In a single UK hospital trust, current smokers had reduced odds of being hospitalised with COVID-19 compared with other respiratory viruses a year previous, although it is unclear whether this association is causal. Targeted post-discharge recording of smoking status may account for the greater EHR-medical notes concordance observed in cases compared with controls.

Keywords

tobacco, smoking, respiratory infections, COVID-19, case-control study, hospitalisation

Revised Amendments from Version 2

This version of the article contains a clarification about exposure classification in instances where discrepancies were observed between the EHR and the contemporaneous medical notes (Methods section), in addition to a reference to the US Surgeon General’s 2014 report (Discussion section).

See the authors' detailed response to the review by Jonathan M. Samet
See the authors' detailed response to the review by Maria Rosaria Galanti

Introduction

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. There are in excess of 118 million confirmed COVID-19 cases globally, with over 2.6 million deaths reported (Johns Hopkins Coronavirus Resource Center, 2021). Large age and sex differences in case severity and mortality have been observed (Guan et al., 2020), with hypertension, diabetes and obesity identified as important risk factors (Fang et al., 2020). There are a priori reasons to believe that current smokers are at increased risk of contracting COVID-19 and experiencing greater disease severity once infected. SARS-CoV-2 enters epithelial cells through the ACE-2 receptor (Hoffmann et al., 2020). Evidence suggests that gene expression and subsequent ACE-2 receptor levels are elevated in the airway and oral epithelium of current smokers (Brake et al., 2020; Cai, 2020), potentially making smokers vulnerable to contracting SARS-CoV-2. Other studies, however, show that smoking downregulates the ACE-2 receptor (Oakes et al., 2018). In addition, smoking involves repeated hand-to-mouth movements, which may mean that smokers are more likely to contract respiratory viruses such as SARS-CoV-2 (Simons et al., 2020a). Early data from the ongoing pandemic have not provided clear evidence for an association of smoking status with COVID-19 outcomes, with a living review and unadjusted Bayesian meta-analysis of over 60 studies indicating that current smokers, compared with those who had never smoked, may be at reduced risk of SARS-CoV-2 infection, while former smokers are at increased risk of hospitalisation, disease severity and in-hospital mortality compared with those who had never smoked (Simons et al., 2021a).

Most studies to date have been limited by the lack of appropriate controls, poor recording of smoking status and insufficient adjustment for relevant covariates. Many studies relied on routine electronic health records (EHRs) to obtain data on demographic characteristics, comorbidities and smoking status. This is problematic, as previous research suggests that data on smoking status obtained via EHRs tend to be incomplete or inaccurate, with implausible longitudinal changes observed (Polubriaginof et al., 2018). As hospitalised populations differ by age and sex from the general population (Secondary Care Analytical Team, 2020), comparisons of current and former smoking prevalence in hospitalised and non-hospitalised populations are likely biased. There is therefore a need for alternative study designs with relevant comparator groups and adjustment for covariates to better understand the association of smoking status with COVID-19 disease outcomes.

However, the selection of an appropriate comparator group is not straightforward. Ideally, controls should represent the underlying population from which cases emerged, both geographically and demographically (Grimes and Schulz, 2005). In the context of COVID-19 hospitalisation, disease severity and death, we therefore reasoned a priori that historical controls – i.e. patients hospitalised at the same trust with another respiratory viral infection (e.g. influenza) a year previous – would act as a useful comparator, as they represent a geographically matched population at risk of severe disease from a circulating respiratory virus with a similar route of transmission (i.e. respiratory droplets and aerosols) and detection (i.e. laboratory-confirmed infection prior to or upon hospitalisation) (McCarthy and Giesecke, 1999). In addition, risk factors for hospitalisation with other respiratory viruses are similar to those for hospitalisation with COVID-19 (e.g. older age, comorbidities) (Falsey et al., 2014; Peralta et al., 2010).

In the present case-control study, we therefore first aimed to examine the association of smoking status with hospitalisation for COVID-19 compared with hospitalisation for other respiratory viral infections (e.g. influenza, respiratory syncytial virus) a year previous at a single UK hospital trust. Second, we aimed to examine whether there is a discordance between smoking status recorded on the summary EHR and within the contemporaneous medical notes. As current smoking in April 2020 (when our study protocol was registered) was a priori expected to be associated with an increased risk of COVID-19 hospitalisation (Alqahtani et al., 2020; Simons et al., 2020a), and with the association expected to be of a similar magnitude to that observed for other respiratory viruses, we opted for a non-inferiority design to test the hypothesis that the proportion of current smokers in patients hospitalised with COVID-19 is similar to that in patients hospitalised with other respiratory viral infections a year previous.

Methods

Ethics statement

This study was approved by the UCL/UCLH Joint Research Office Research Strategy Group and UCLH Data Access Committee. Approval to conduct research limited to pseudonymised patient data was provided by the NHS Health Research Authority (IRAS_282704). The requirement for informed consent was waived by the NHS Health Research Authority due to the observational nature of the study.

Study design

This was an observational case-control study with historical controls, performed at a single National Health Service (NHS) hospital trust (comprising two hospital sites) in London, UK. The study protocol and analysis plan were pre-registered on the Open Science Framework in April 2020 (Simons et al., 2020a). The pre-registered protocol stipulated a non-inferiority design (i.e. a one-tailed statistical test) to maximise statistical power to detect a significantly lower proportion of current smokers (i.e. <10%) among patients hospitalised with COVID-19 compared with patients hospitalised with another respiratory viral infection a year previous (i.e. 20%). The protocol was amended after data collection but prior to statistical analysis in September 2020 to implement a traditional case-control design (i.e. a two-tailed statistical test), as a delay in study approval meant that the number of eligible cases and controls exceeded our expectations; providing sufficient power for a two-tailed test. We had also planned to compare current smoking in cases with age- and sex-matched London prevalence, with data obtained from the representative Annual Population Survey. However, following an external review on an earlier manuscript draft, we decided against presenting data from this comparison due to smoking rates in hospitalised populations typically being greater than in the general population (Benowitz et al., 2009).

A sample size calculation, updated after data collection but prior to data analysis, indicated that 363 cases and 109 controls would provide 80% power to detect a 10% difference in current smoking prevalence in cases compared with controls (e.g. 10% in cases and 20% in controls) with alpha set to 5%. We included all cases from 1st March 2020 to the 26th August 2020 (the date on which data were obtained) and all controls from the 1st January 2019 and the 31st December 2019.

Eligibility criteria

Inclusion criteria

Cases

  • 1. Consecutive patients admitted to an adult hospital ward (i.e. 18+ years) between 1st March 2020 and 26th August 2020 (the date on which data were obtained).

  • 2. Diagnosis of COVID-19 on or within five days of hospital admission, identified via associated International Classification of Diseases version 10 (ICD-10) codes (World Health Organisation, 2019). This temporal boundary was set to prevent inclusion of patents with nosocomial (hospital-acquired) infection and allowed for a delay of three days in requesting a COVID-19 test and two days for receiving and reporting the results on the EHR. The median incubation time for COVID-19 is estimated at 5.1 days (95% CI = 4.5-5.8) (Lauer et al., 2020). We sought to exclude individuals with nosocomial COVID-19 infection as they are a different population (e.g. older, more frail) compared with those infected in the community and subsequently requiring hospitalisation.

Controls

  • 1. Consecutive patients admitted to an adult hospital ward (i.e. 18+ years) between 1st January 2019 and 31st December 2019.

  • 2. Diagnosis of a viral respiratory infection (e.g. influenza, parainfluenza) on or within 5 days of admission, identified via ICD-10 codes.

Exclusion criteria

  • 1. No record of smoking status on the summary EHR or within the medical notes.

  • 2. A primary diagnosis of infectious exacerbation of chronic obstructive pulmonary disease (COPD) due to the strong causal association of COPD with current and former smoking.

Measures

Data on demographic and smoking characteristics were collected from the summary EHR or the medical notes. In the UK, the summary EHR is produced at the point of an individual's first interaction with a specific NHS hospital trust. Further information is added to the summary EHR following subsequent interactions with the hospital trust. The medical notes include contemporaneous clinical notes, General Practitioner referral letters and outpatient clinic letters, and are updated more frequently than the summary EHR.

Outcome variable

The outcome of interest was the type of hospital admission (i.e. with COVID-19 vs. other respiratory viral infections a year previous).

Exposure variable

Smoking status (i.e. current, former, never) was obtained from the summary EHR or the medical notes. A number of cases were recorded as ‘non-smokers’ without distinguishing between ‘former smokers’ and ‘never smokers’. For the primary analysis, patients categorised as a ‘non-smoker’ were treated as ‘never smokers’. Where possible, information on use of smokeless tobacco, waterpipe and/or alternative nicotine products (e.g. e-cigarettes) was extracted. We searched within the contemporaneous medical records for free-text entries of smoking status. The most recent record of smoking status, obtained from either the summary EHR or the contemporaneous medical notes, was extracted. Where there was discordance between the summary EHR and the contemporaneous medical notes, smoking status was classified based on the contemporaneous medical notes (as this clinician obtained information was assumed to be more recent and therefore accurate). Where available, data on pack-year history of smoking (i.e. the number of packs of cigarettes smoked per day multiplied by the number of years of smoking, with a pack equal to 20 cigarettes) were extracted.

Covariates

Covariates included age, sex, ethnicity, socioeconomic position (SEP; with post codes linked by the research team to the Index of Multiple Deprivation (IMD) (Department for Communities and Local Government, 2019)) and comorbidities (classified by organ system, including cardiac, metabolic and respiratory diseases). Medical conditions not expected to be strongly associated with COVID-19 hospitalisation were not considered in the analyses (e.g. sciatica and fibromyalgia; see Extended data). Age was treated as a continuous variable in the primary analysis, with banded age groups (i.e. 18-29 years, 30-44 years, 45-59 years, 60-74 years, 75-89 years and > 90 years) used in exploratory analyses. The IMD was categorised as quintiles to reduce the impact of sparse data.

Data analysis

All analyses were conducted in R version 4.0.2. (R Core Team, 2020). Descriptive statistics for cases and controls are reported. To explore differences between cases and controls, Pearson’s Chi-square tests, Cochran-Armitage tests for trend and ANOVAs were used, as appropriate.

To examine the association of former and current smoking with hospitalisation for COVID-19 compared with hospitalisation for other respiratory viral infections, unadjusted and two different adjusted generalised linear models with a binomial distribution and logit link function were performed. The first model adjusted for age, sex and SEP, with a second model adjusting for age, sex, SEP and comorbidities. We report odds ratios (ORs), 95% confidence intervals (CIs) and p-values. Two sensitivity analyses were subsequently performed. First, those recorded as ‘non-smokers’ were removed from the analysis. Second, those excluded from the analytic sample due to missing data on smoking status (see section above on ‘Exclusion criteria’) were included and coded as i) ‘never smokers’ and then as ii) ‘current smokers’ to assess the robustness of the associations.

To examine the concordance between smoking status recorded on the summary EHR and within the contemporaneous medical notes, Pearson’s Chi-squared tests were performed for the entire sample, and then separately for cases and controls.

Results

A total of 610 potential cases and 514 potential controls were identified. A total of 446 cases and 211 controls were included in the analytic sample (see Figure 1). In total, 13 potential controls and 60 potential cases were excluded due to not having a record of documented smoking status. This was likely due to patients having no prior contact with the NHS foundation trust. Notably, 37 (62%) potential cases that were excluded because of missing smoking status did not survive to hospital discharge, with no in-hospital mortality in potential controls, which suggests that data may be missing due to increased mortality in cases.

608a1d8b-65cd-422c-9203-1d5990d6bfdf_figure1.gif

Figure 1. Eligibility flow diagram for controls (left hand side) and cases (right hand side).

Compared with controls, cases were more likely to be male (55% vs. 35.9%) and older (64.9 years vs 62.5 years) (see Table 1). Approximately 10% of cases and controls had missing data for ethnicity. Compared with cases, controls were more likely to be admitted from more deprived areas (IMD quintiles 1 and 2) (41.8% vs. 32.9%, p < 0.001). Cases were more likely than controls to have pre-existing metabolic (30.3% vs 13.3%) and cardiac comorbidities (53.4% vs 30.3%). A significantly larger proportion of cases compared with controls did not survive to discharge (28.7% vs. 4.3%). Among 128 cases not surviving to discharge, 53 (41.4%) were never smokers, 63 (49.2%) were former smokers and 12 (9.4%) were current smokers. For patients who survived to discharge, the median length of hospital stay for cases and controls was 9 (IQR = 4-18) and 4 (IQR = 2-9) days, respectively (see Table 1).

Table 1. Demographic and smoking characteristics of cases and controls.

Controls (N = 211)Cases (N = 446)Total (N = 657)p value
Female sex116 (55.0%)160 (35.9%)276 (42.0%)<0.001
Age in years (continuous)0.019
- Median (IQR)62.5 (48.5-75.8)64.9 (52.4-76.2)64.58 (51.3-76.1)
Age in years (banded)0.007
- 18-2918 (8.5%)11 (2.5%)29 (4.4%)
- 30-4422 (10.4%)37 (8.3%)59 (9.0%)
- 45-5946 (21.8%)113 (25.3%)159 (24.2%)
- 60-7467 (31.8%)162 (36.3%)229 (34.9%)
- 75+58 (27.5%)123 (27.6%)181 (27.5%)
Ethnicity0.243
- Black British, Black African or Black Caribbean19 (9.0%)63 (14.1%)82 (12.5%)
- White British or White Other116 (55.0%)220 (49.3%)336 (51.1%)
- Not stated26 (12.3%)43 (9.6%)69 (10.5%)
- Asian British or Asian28 (13.3%)68 (15.2%)96 (14.6%)
- Other22 (10.4%)52 (11.7%)74 (11.3%)
IMD quintile0.06
- Missinga5 (2.4%)5 (1.1%)10 (1.5%)
- 1 - Most deprived21 (10.0%)26 (5.8%)47 (7.2%)
- 267 (31.8%)121 (27.1%)188 (28.6%)
- 342 (19.9%)122 (27.4%)164 (25.0%)
- 438 (18.0%)98 (22.0%)136 (20.7%)
- 5 - Least deprived38 (18.0%)74 (16.6%)112 (17.0%)
Most recent record of smoking status (summary EHR or medical notes)0.012
- Never smoker108 (51.2%)232 (52.0%)340 (51.8%)
- Former smoker67 (31.8%)172 (38.6%)239 (36.4%)
- Current smoker36 (17.1%)42 (9.4%)78 (11.9%)
Record of pack-year smoking history in former and current smokers36 (35%)91 (42.5%)127 (40%)
- Pack-year smoking history in current smokers, median (IQR)30 (22.5-45)30 (6-45)30 (16.8-45.5)
- Pack-year smoking history in former smokers, median (IQR)20 (10-40)25 (10-40)25 (10-40)
Recorded smoking status on summary EHR<0.001
- Never smoker23 (10.9%)233 (52.2%)256 (39.0%)
- Former smoker22 (10.4%)152 (34.1%)174 (26.5%)
- Current smoker7 (3.3%)30 (6.7%)37 (5.6%)
- Unknown159 (75.4%)31 (7.0%)190 (28.9%)
Survival to discharge202 (95.7%)318 (71.3%)520 (79.1%)<0.001
Length of hospital admission for survivors (days)<0.001
- Median (IQR)4 (2-9)9 (4-18)7 (3-14)
Cancer (current or past)66 (31.3%)90 (20.2%)156 (23.7%)0.002
Auto-immune disease (present)12 (5.7%)16 (3.6%)28 (4.3%)0.213
Metabolic disease (present)28 (13.3%)135 (30.3%)163 (24.8%)<0.001
Haematological disease (present)3 (1.4%)4 (0.9%)7 (1.1%)0.541
Cardiac disease (present)64 (30.3%)238 (53.4%)302 (46.0%)<0.001
Neurological disease (present)24 (11.4%)54 (12.1%)78 (11.9%)0.786
Respiratory disease (present)54 (25.6%)91 (20.4%)145 (22.1%)0.134
Renal disease (present)12 (5.7%)37 (8.3%)49 (7.5%)0.235
HIV (present)2 (0.9%)7 (1.6%)9 (1.4%)0.522
No relevant comorbidities43 (20.4%)85 (19.1%)128 (19.5%)0.690

a IMD is not available for individuals with home addresses outside of England.

Cases and controls were predominantly admitted from North central and North East central London (see Extended data, Figure S1). The number of cases admitted from peripheral locations was greater than in controls and represents transfer of inpatients from other hospitals and diversion of patients that would otherwise have attended local hospitals due to bed pressures. The Chi-square test for trend found inconclusive evidence for any difference in SEP between cases and controls, χ2(3) = 8.93, p = 0.06 (see Extended data).

Association of smoking status with type of hospitalisation

The prevalence of former smoking was higher in cases compared with controls (38.6% vs. 31.8%). Current smoking prevalence was lower in cases compared with controls (9.4% vs. 17.1%). A single patient from the case sample was recorded as a dual cigarette and e-cigarette user. Two patients, one from each sample, were recorded as dual cigarette and shisha/waterpipe users. Pack-year history of smoking was only recorded for 40% of patients with a smoking history (see Table 1).

In the univariable analysis, current smokers had reduced odds of being hospitalised with COVID-19 compared with other respiratory viruses a year previous (OR = 0.52, 95% CI = 0.31-0.86, p = 0.01). The odds for former smokers were equivocal (OR = 1.16, 95% CI = 0.81-1.68, p = 0.43).

In the multivariable analysis adjusted for sex, age and SEP, current smokers had reduced odds of being hospitalised with COVID-19 compared with other respiratory viruses a year previous (OR = 0.48, 95% CI = 0.28-0.83, p < 0.01). There was no significant association among former smokers (OR = 0.90, 95% CI = 0.61-1.34, p = 0.61). Results were not materially altered when also adjusting for relevant comorbidities (current smokers, OR = 0.55, 95% CI = 0.31-0.96, p = 0.04; former smokers, OR = 1.08, 95% CI = 0.72-1.61, p = 0.70).

Sensitivity analyses

First, in a sensitivity analysis with patients recorded as ‘non-smokers’ excluded from the sample (leaving 398 cases and 159 controls), current smokers had reduced odds of being hospitalised with COVID-19 compared with other respiratory viruses a year previous (OR = 0.41, 95% CI = 0.22-0.74, p = 0.03). There was no significant association among former smokers (OR = 0.78, 95% C.I. = 0.49-1.23, p = 0.28).

Second, in a sensitivity analysis with those with missing data on smoking status (n = 73) treated as ‘never smokers’ (resulting in 506 cases and 224 controls), patients hospitalised with COVID-19 had reduced odds of being a current smoker compared with those admitted with other respiratory viruses (OR = 0.51, 95% CI = 0.30-0.88, p = 0.01). Next, when those with missing data on smoking status were treated as ‘current smokers’, there was no significant association between current smoking and hospitalisation with COVID-19 (OR = 0.94, 95% CI = 0.61-1.46, p = 0.80).

Third, in a sensitivity analysis removing SEP from the multivariable model, retaining sex and age only, current smokers had reduced odds of being hospitalised with COVID-19 compared with other respiratory viruses a year previous (OR = 0.51, 95% CI = 0.31-0.86, p < 0.01). There was no significant association among former smokers (OR = 0.95, 95% CI = 0.65-1.40, p = 0.80).

Concordance of smoking status recorded on the summary EHR and the medical notes

Controls were more likely to have no record of smoking status on the summary EHR compared with cases (75.4% vs. 7%) (see Figure 2). However, smoking status could be ascertained from the contemporaneous medical notes for all included cases and controls. Smoking status on the summary EHR (including ‘unknown’ status) was incorrectly recorded for 168 (79.6%) controls and 60 cases (13.5%) (χ2(3) = 226.7, p = < 0.001). In cases, six current smokers were misclassified as former smokers, one current smoker as a never smoker and six current smokers had no record of smoking status on the summary EHR. In controls, six current smokers were misclassified as former smokers and 23 current smokers had no record of smoking status on the summary EHR. There was greater discordance between smoking status recorded on the summary EHR and within the contemporaneous medical notes in controls (χ2(3) = 256.5, p = < 0.001) than in cases (χ2(3) = 34.2, p = < 0.001).

608a1d8b-65cd-422c-9203-1d5990d6bfdf_figure2.gif

Figure 2. Concordance between smoking status recorded on the summary EHR and the medical notes for controls (red) and cases (blue).

Discussion

This observational case-control study with patients admitted to a single UK hospital trust found a lower proportion of current smokers in cases hospitalised with COVID-19 during the first phase of the pandemic compared with controls hospitalised with other respiratory viral infections a year previous. Further, we found that smoking status is typically poorly recorded in the summary EHR. This was more prominent in controls than cases – a difference that is likely explained by the observation that COVID-19 patients were followed up by the respiratory medicine team after discharge, as part of a COVID-19 follow-up clinic where they specifically asked about smoking status (Mandal et al., 2020). The observed discrepancy between smoking status recorded on summary EHRs and the contemporaneous medical notes is a concern, particularly for studies relying solely on EHRs as the source of information on smoking status.

A living review and unadjusted Bayesian meta-analysis of observational studies conducted during the COVID-19 pandemic, up-to-date as of July 2021, has found that current smokers appear to be at reduced risk of COVID-19 infection, but that there is as inconclusive evidence of an increased risk of more severe disease among smokers who are infected. In addition, former smokers appear to be at increased risk of severe disease and mortality from COVID-19 (Simons et al., 2020b, 2021a).

Strengths and limitations

To our knowledge, this is one of few studies specifically designed to examine the association between smoking status and hospitalisation with COVID-19. It was further strengthened by an assessment of the quality of data on smoking status gleaned from summary EHRs.

However, this study has several important limitations, the majority of which pertain to the selection of the controls. First, current smoking is expected a priori to be associated with hospitalisation for non-COVID-19 respiratory viruses (Stämpfli & Anderson, 2009). As concluded in the US Surgeon General’s 2014 report, smoking and infection with acute respiratory illnesses (including pneumonia) appear causally related. However, evidence as to the association between smoking and increased disease severity (once infected) is currently lacking. Ideally, hospital-based case-control studies should avoid selecting a control disease which is associated with the exposure of interest (i.e. smoking status) (Vandenbroucke & Pearce, 2012). However, to our knowledge, there is no other control disease with a similar route of acquisition and mechanism for hospitalisation/severe disease that is not a priori also associated with smoking status. The greater smoking prevalence in controls compared with the general population from which the cases emerged (Vandenbroucke & Pearce, 2012) therefore likely contributes to the significantly reduced odds of current smoking in our cases.

Second, the risk profile for controls likely differs from cases in that there is prior immunity to other respiratory viruses (e.g. influenza, respiratory syncytial virus), with no prior immunity in the population to SARS-CoV-2.

Third, we selected the controls on the basis of sharing a similar route of transmission and risk factors for hospitalisation as cases. However, at the time of writing (March 2021), we now suspect that COVID-19 differs from other respiratory viruses in several ways. For example, COVID-19 gains cell entry via the ACE-2 receptor (Hoffmann et al., 2020), with unknown receptor binding in flu (Killingley & Nguyen-Van-Tam, 2013) and appears to display less fomite and physical contact transmission than flu (Ben-Shmuel et al., 2020). In addition, emerging evidence suggests that COVID-19 has a significantly different pathological process compared with other respiratory viruses. For example, mortality rates from COVID-19 differ widely from those due to epidemic influenza (Office for National Statistics, 2020a). Although we currently do not know the importance of these factors, taken together, emerging observations may mean that direct comparison of risk profiles in cases and controls is limited.

Fourth, while no known behavioural restrictions were implemented during the control period, London was under lockdown restrictions from March to July 2020, which likely impacted the risk of viral exposure in cases (Davies et al., 2020). This may further have impacted the different risk profiles of controls and cases beyond the adjustments made in this analysis for sex, age and SEP.

Fifth, hospital admission routines were severely disrupted in many countries during the early stages of the COVID-19 pandemic (e.g., patient transfer between hospitals, altered admission criteria). This may have influenced patient selection and/or the recording of smoking status. With regards to patient selection, albeit possible, we are unaware of evidence from UK hospitals of patient characteristics correlated with smoking (e.g., age, SEP) determining whether a patient would be admitted, rather than their clinical situation on presentation. For example, smoking status has not been included in a widely used hospital-based algorithm for predicting clinical deterioration from COVID-19 (i.e., the ISARIC-4C deterioration score; Gupta et al., 2021). With regards to the recording of smoking status, to the best of our knowledge, the admission routines (including the medical history taking) within the selected hospital trust remained stable during the pandemic. However, patients admitted with COVID-19 may generally have been more unwell at the point of admission compared with controls, which may have led to less accurate documentation of smoking status. This potential bias was somewhat reduced by those surviving their COVID-19 illness being followed up through a specialised respiratory medicine clinic implemented during the pandemic, with smoking status ascertained during follow-up calls/visits. However, the finding that COVID-19 patients with unknown (compared with those with recorded) smoking status had greater in-hospital mortality means that residual bias cannot be ruled out. A sensitivity analysis with all missing assumed to be current smokers made the negative association of smoking status and COVID-19 go away. However, it should be noted that this is a very strong assumption, unlikely to hold true.

Sixth, the selection of historical controls may mean that there are non-trivial differences in smoking status between controls and cases due to a declining trend in London smoking prevalence (Office for National Statistics, 2020b). However, a single year was used for the selection of controls, and there was no important change in smoking prevalence among all (Jackson et al., 2021), so we expect any potential impact of pandemic-related trends in smoking prevalence on the results to be minimal. We considered using a contemporaneous control (i.e. patients hospitalised with other respiratory viral infections in 2020), which would have mitigated against this potential bias. However, due to factors such as reduced national and international travel, physical distancing, increased hand hygiene and potential viral dominance by COVID-19, exposure to and hospitalisation with other respiratory viruses has been substantially reduced in 2020 (GOV.UK, 2020), which would have limited the sample size for controls.

Seventh, given the broad and currently poorly understood COVID-19 pathology following SARS-CoV-2 infection, it was not possible to differentiate patients presenting to hospital due to COVID-19 or those admitted for other reasons. This may have introduced additional bias in that individuals may have been admitted to hospital with co-incident SARS-CoV-2 infection that was not associated with their current health need. We tried to mitigate this by only including cases if they had a positive COVID-19 test result less than 5 days from their date of hospital admission.

Eighth, a history of current or past cancer was high in both groups at greater than 20% and was significantly greater in controls compared with cases. This reflects a bias in the population that regularly interacts with the selected NHS hospital trust, which is a specialist cancer referral centre. We visualised the geographic regions where patients were admitted from to examine any systemic differences between cases and controls, and caution that the differing catchment areas of the two samples may have led to important differences in the underlying populations. In addition, during the peak of the first wave of the pandemic in the UK (i.e. March-April 2020), many cases were transferred across hospital sites due to bed pressures (Dunhill, 2020).

Finally, we have argued elsewhere that studies that aim to elucidate the potential causal relationship between smoking status and COVID-19 should first clarify the mechanism(s) through which smoking and/or nicotine use is expected to influence COVID-19 infection and/or disease outcomes contingent on infection and plan their studies accordingly (Perski et al., 2021). Considering these reflections, and following constructive peer review, we acknowledge that the present study through its selection of the control sample does not distinguish between two potential mechanisms: comparable exposure to SARS-CoV-2 virus with differential infection in current compared with never smokers, and comparable SARS-CoV-2 infection with differential hospitalisation in current compared with never smokers. Future research should aim to isolate these potential mechanisms by design, thus getting closer to unbiased estimates of the association of smoking/nicotine use with COVID-19 outcomes. However, we note that – given the time-varying dynamics of respiratory viruses – it would be incredibly challenging to design a representative study to compare rates of infection in those with similar exposure using available datasets. Similarly, as data linkage of representative infection surveys with hospital records is also limited at present, designing a study to examine the second potential pathway (i.e., examining hospitalisation rates in a representative sample of those infected) would also be very challenging.

Despite these limitations, alternative designs were impracticable or would have had different limitations. In the future, the current study can be considered alongside findings across multiple such alternative methodological approaches, each with different sources of bias, to triangulate on the extent to which associations between smoking and COVID-19 are causal.

Implications for policy and practice

COVID-19 will continue to place a large burden on healthcare services in the UK and internationally over the coming months and years. To mitigate against this, multiple non-pharmacological interventions are being implemented to reduce the intensity of demand on acute and intensive services. Irrespective of any direct link between smoking and COVID-19 disease outcomes, smoking is a significant cause for healthcare demand globally. We have argued elsewhere for the need to ramp up smoking cessation support to reduce the current and future burden on healthcare and social services (Simons et al., 2020a).

Avenues for future research

The selection of appropriate controls in hospital-based case-control studies is very challenging for a novel respiratory virus such as COVID-19 (which means we converged on a hybrid approach, combining elements from hospital-based case series and case-control designs with historical controls). We recommend the use of representative population-studies with data from multiple sites and with purposeful acquisition of smoking status, to better understand the role of smoking as a potential risk or protective factor for COVID-19 hospitalisation and disease severity.

Conclusion

In a single hospital trust in the UK, patients hospitalised with COVID-19 had lower odds of appearing as smokers compared with patients with other respiratory viruses a year previous, although we caution against interpreting this as a causal association. Smoking status was poorly recorded, with high observed discordance between smoking status recorded on the summary EHR and the contemporaneous medical notes.

Data availability

Underlying data

Due to the sensitive nature of the data, we do not have ethical approval to release the individual-level data underpinning the analyses. Anonymised and de-identified individual-level data are available upon request from the corresponding author to bona fide researchers and following approval from the Biomedical Research Centre Clinical and Research Informatics Unit at University College London Hospital NHS foundation trust.

Extended data

OSF: Association of smoking status with hospitalisation for COVID-19 compared with other respiratory viruses a year previous: a case-control study at a single UK National Health Service trust: Protocol. https://doi.org/10.17605/OSF.IO/84VYD (Simons et al., 2021b).

This project contains the following extended data:

  • - Date file 1. (Extended data, PDF format)

  • - Data file 2. (Protocol, docx format)

Data are available under the terms of the Creative Commons Attribution 4.0 International (CC-By Attribution 4.0 International).

Comments on this article Comments (1)

Version 3
VERSION 3 PUBLISHED 17 Jan 2022
Revised
Version 1
VERSION 1 PUBLISHED 24 Aug 2021
Discussion is closed on this version, please comment on the latest version above.
  • Reader Comment 27 Aug 2021
    Mohammad Ali, Uttara Adhunik Medical College and Hospital, Dhaka, Bangladesh
    27 Aug 2021
    Reader Comment
    This study's results amazed me. Other studies found a strong association between smoking and hospitalization from COVID-19. Interestingly, we found an association between current smoking status and COVID-19 vaccine hesitancy. ... Continue reading
  • Discussion is closed on this version, please comment on the latest version above.
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Simons D, Perski O, Shahab L et al. Association of smoking status with hospitalisation for COVID-19 compared with other respiratory viruses a year previous: a case-control study at a single UK National Health Service trust [version 3; peer review: 2 approved]. F1000Research 2022, 10:846 (https://doi.org/10.12688/f1000research.55502.3)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 3
VERSION 3
PUBLISHED 17 Jan 2022
Revised
Views
23
Cite
Reviewer Report 27 Jan 2022
Jonathan M. Samet, Colorado School of Public Health, Aurora, CO, USA 
Approved
VIEWS 23
My two remaining concerns have been satisfactorily ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Samet JM. Reviewer Report For: Association of smoking status with hospitalisation for COVID-19 compared with other respiratory viruses a year previous: a case-control study at a single UK National Health Service trust [version 3; peer review: 2 approved]. F1000Research 2022, 10:846 (https://doi.org/10.5256/f1000research.120034.r120026)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 2
VERSION 2
PUBLISHED 15 Nov 2021
Revised
Views
15
Cite
Reviewer Report 25 Nov 2021
Maria Rosaria Galanti, Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden 
Approved
VIEWS 15
The authors did a considerable effort to comply with ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Galanti MR. Reviewer Report For: Association of smoking status with hospitalisation for COVID-19 compared with other respiratory viruses a year previous: a case-control study at a single UK National Health Service trust [version 3; peer review: 2 approved]. F1000Research 2022, 10:846 (https://doi.org/10.5256/f1000research.79264.r100232)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
28
Cite
Reviewer Report 16 Nov 2021
Jonathan M. Samet, Colorado School of Public Health, Aurora, CO, USA 
Approved with Reservations
VIEWS 28
  1. With regard to the exposure classification, in the instances when the notes and the HER were in disagreement, how was exposure classified?  There does not seem to be a specification as to how this situation was handled.
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Samet JM. Reviewer Report For: Association of smoking status with hospitalisation for COVID-19 compared with other respiratory viruses a year previous: a case-control study at a single UK National Health Service trust [version 3; peer review: 2 approved]. F1000Research 2022, 10:846 (https://doi.org/10.5256/f1000research.79264.r100233)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 17 Jan 2022
    Olga Perski, Department of Behavioural Science and Health, University College London, London, UK
    17 Jan 2022
    Author Response
    Thank you for your helpful comments.

    With regard to the exposure classification, in the instances when the notes and the HER were in disagreement, how was exposure classified?  There ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 17 Jan 2022
    Olga Perski, Department of Behavioural Science and Health, University College London, London, UK
    17 Jan 2022
    Author Response
    Thank you for your helpful comments.

    With regard to the exposure classification, in the instances when the notes and the HER were in disagreement, how was exposure classified?  There ... Continue reading
Version 1
VERSION 1
PUBLISHED 24 Aug 2021
Views
24
Cite
Reviewer Report 08 Oct 2021
Jonathan M. Samet, Colorado School of Public Health, Aurora, CO, USA 
Not Approved
VIEWS 24
General Comments:

This paper describes the findings of a hospital-based case-control study on cigarette smoking on risk for hospitalization from COVID-19. The paper is lacking a clear explication of the underlying hypothesis, which is critical to determining what ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Samet JM. Reviewer Report For: Association of smoking status with hospitalisation for COVID-19 compared with other respiratory viruses a year previous: a case-control study at a single UK National Health Service trust [version 3; peer review: 2 approved]. F1000Research 2022, 10:846 (https://doi.org/10.5256/f1000research.59083.r94125)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 15 Nov 2021
    Olga Perski, Department of Behavioural Science and Health, University College London, London, UK
    15 Nov 2021
    Author Response
    This paper describes the findings of a hospital-based case-control study on cigarette smoking on risk for hospitalization from COVID-19. The paper is lacking a clear explication of the underlying hypothesis, ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 15 Nov 2021
    Olga Perski, Department of Behavioural Science and Health, University College London, London, UK
    15 Nov 2021
    Author Response
    This paper describes the findings of a hospital-based case-control study on cigarette smoking on risk for hospitalization from COVID-19. The paper is lacking a clear explication of the underlying hypothesis, ... Continue reading
Views
40
Cite
Reviewer Report 13 Sep 2021
Maria Rosaria Galanti, Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden 
Not Approved
VIEWS 40
This was a case-control study aiming at shedding light on the potential causal association between tobacco smoking and hospitalization because of COVID-19. In the light of the controversial associations between smoking and risk for infection with SARS-COV-2 on the one ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Galanti MR. Reviewer Report For: Association of smoking status with hospitalisation for COVID-19 compared with other respiratory viruses a year previous: a case-control study at a single UK National Health Service trust [version 3; peer review: 2 approved]. F1000Research 2022, 10:846 (https://doi.org/10.5256/f1000research.59083.r92725)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 15 Nov 2021
    Olga Perski, Department of Behavioural Science and Health, University College London, London, UK
    15 Nov 2021
    Author Response
    This was a case-control study aiming at shedding light on the potential causal association between tobacco smoking and hospitalization because of COVID-19. In the light of the controversial associations between ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 15 Nov 2021
    Olga Perski, Department of Behavioural Science and Health, University College London, London, UK
    15 Nov 2021
    Author Response
    This was a case-control study aiming at shedding light on the potential causal association between tobacco smoking and hospitalization because of COVID-19. In the light of the controversial associations between ... Continue reading

Comments on this article Comments (1)

Version 3
VERSION 3 PUBLISHED 17 Jan 2022
Revised
Version 1
VERSION 1 PUBLISHED 24 Aug 2021
Discussion is closed on this version, please comment on the latest version above.
  • Reader Comment 27 Aug 2021
    Mohammad Ali, Uttara Adhunik Medical College and Hospital, Dhaka, Bangladesh
    27 Aug 2021
    Reader Comment
    This study's results amazed me. Other studies found a strong association between smoking and hospitalization from COVID-19. Interestingly, we found an association between current smoking status and COVID-19 vaccine hesitancy. ... Continue reading
  • Discussion is closed on this version, please comment on the latest version above.
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.